Bioneer : Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
August 01, 2022 at 03:24 am EDT
Share
Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
※ The information contained in this report is estimated, it is subject to change according to actual settlement.
1. Details of Business Performance
Classification(unit : Mil.KRW, %)
Current Term
Previous Term
Amount Increased/Decreased Compared to the Preceding Period(Increase/Decrease Rate)
Corresponding Period of The Previous Year
Amount Increased/Decreased Compared to the Corresponding Period of The Previous Year (Increase/Decrease Rate)
('22.2Q)
('22.1Q)
('21.2Q)
Sales
Amount
52,561
61,454
-8,893
(-14.47%)
54,109
-1,548
(-2.86%)
Accumulated Amount
114,015
-
-
103,991
10,024
9.64%
Operating Income
Amount
43
10,399
-10,356
(-99.59%)
22,644
-22,601
(-99.81%)
Accumulated Amount
10,443
-
-
40,792
-30,349
(-74.40%)
Profit from continuing operation before corporate income tax
Amount
1,791
11,655
-9,864
(-84.63%)
23,198
-21,407
(-92.28%)
Accumulated Amount
13,446
-
-
43,474
-30,028
(-69.07%)
Net Income
Amount
1,242
9,137
-7,895
(-86.41%)
17,369
-16,127
(-92.85%)
Accumulated Amount
10,379
-
-
32,679
-22,300
(-68.24%)
Net Income Attributable to the Shareholders of the Parent Company
Amount
-
-
-
-
-
Accumulated Amount
-
-
-
-
-
-
-
-
-
-
-
2. Details of Information Released
Information Providers
IR/PR Division
Information Recipients
Domestic and foreign investors
Date&Time of Information Released
Frequent provision after the date of public announcement.
Title and Place of Event held
-
3. Contact Points
Disclosure Officer (tel.)
Doo Hyun Hwang Vice President(02-739-6083)
Disclosure Staff (tel.)
Jae Chul Song General Manager (02-739-6084)
Dept. Name (tel.)
IR/PR Division(02-739-6083)
4. Other references useful for making investment decisions
- The performance above is a preliminary estimate based on consolidation standards prepared following K-IFRS.
- The performance above is an estimate prepared for the investors' convenience before the accounting review of external auditors. Hence, the figures may change during the external auditors' review process.
※ Relevant Disclosure
2022-08-01 Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bioneer Corporation published this content on 01 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 August 2022 07:23:04 UTC.
BIONEER CORPORATION is a Korea-based company engaged in the biotechnology business. The Company mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. It also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The Company operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.